Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06856343
Recruiting Observational

REBECCA Real-world Early BrEast CanCer mAnagement

NCT06856343 · tracked via the Priya Life Science France tracker
Sponsor
AstraZeneca
Phase
Observational
Started
2024-12-30
Last updated
2026-08-25

Condition(s) studied

Breast Cancer

Study summary

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female aged ≥ 18 years * Patient diagnosed with HER2-negative eBC * Patient about to be initiated with adjuvant Olaparib at their physician's discretion * Patient has been informed and does not object to participation in the study. Exclusion Criteria: * Patient not consenting to participate. * Patients included in the Early Access Program

Primary outcome measure(s)

  • Proportion of patients who receive Olaparib for the full treatment duration — 18 months after inclusion
    The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.

Trial sites (58)

FacilityCityRegionStatus
Research Site Clermont-Ferrand Auvergne-Rh ne-Alpes Recruiting
Research Site Gleizé Auvergne-Rh ne-Alpes Recruiting
Research Site Grenoble Auvergne-Rh ne-Alpes Not Yet Recruiting
Research Site Lyon Auvergne-Rh ne-Alpes Recruiting
Research Site Metz-Tessy Auvergne-Rh ne-Alpes Recruiting
Research Site Saint-Etienne Auvergne-Rh ne-Alpes Not Yet Recruiting
Research Site Saint-Priest-en-Jarez Auvergne-Rh ne-Alpes Not Yet Recruiting
Research Site Thonon-les-Bains Auvergne-Rh ne-Alpes Recruiting
Research Site Valence Auvergne-Rh ne-Alpes Recruiting
Research Site Valence Auvergne-Rh ne-Alpes Not Yet Recruiting
Research Site Dijon Bourgogne-Franche-Comt Not Yet Recruiting
Research Site Plérin Brittany Region Recruiting
Research Site Rennes Brittany Region Not Yet Recruiting
Research Site Saint-Brieuc Brittany Region Not Yet Recruiting
Research Site Saint-Grégoire Brittany Region Recruiting
Research Site Chambray-lès-Tours Centre-Val de Loire Recruiting
Research Site Saint-Doulchard Centre-Val de Loire Recruiting
Research Site Bezannes Grand Est Recruiting
Research Site Haguenau Grand Est Not Yet Recruiting
Research Site Nancy Grand Est Recruiting
Research Site Beauvais Hauts-de-France Recruiting
Research Site Beuvry Hauts-de-France Recruiting
Research Site Compiègne Hauts-de-France Not Yet Recruiting
Research Site Creil Hauts-de-France Not Yet Recruiting
Research Site Dechy Hauts-de-France Recruiting
Research Site Lille Hauts-de-France Not Yet Recruiting
Research Site Lille Hauts-de-France Not Yet Recruiting
Research Site Saint-Martin-Boulogne Hauts-de-France Not Yet Recruiting
Research Site Salouël Hauts-de-France Recruiting
Research Site Saint-Pierre-des-Corps La R Union Not Yet Recruiting
Research Site FORT de France Cedex Martinique Not Yet Recruiting
Research Site Agen New Aquitaine Not Yet Recruiting
Research Site Libourne New Aquitaine Not Yet Recruiting
Research Site Limoges New Aquitaine Not Yet Recruiting
Research Site Périgueux New Aquitaine Recruiting
Research Site Poitiers New Aquitaine Recruiting
Research Site Caen Normandy Recruiting
Research Site Rouen Normandy Recruiting
Research Site Béziers Occitanie Not Yet Recruiting
Research Site Montpellier Occitanie Recruiting

+ 18 more sites — see the full list on the official registry below.

More AstraZeneca trials in France

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. Recruiting
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer Active, not recruiting
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Active, not recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants Recruiting

Other trials for the same condition

Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer Active, not recruiting
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers Recruiting
Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Aromatase Inhibitor-induced Arthralgia (AIA) Starting soon
Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability Recruiting
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06856343 on ClinicalTrials.gov ↗ ← All trials in France